Among patients with ovarian cancer enrolled in the TOPACIO/KEYNOT-162 study evaluating niraparib and pembrolizumab, tumours from responders typically had features of HRD (mutational signature 3) and increased presence of exhausted CD8 + T cells (immune score) versus non-responders [95]. The gene discussed is CD8A; the disease is neoplasm.